Apogee Therapeutics (APGE) News Today $39.72 +0.47 (+1.20%) Closing price 03/28/2025 04:00 PM EasternExtended Trading$39.72 +0.01 (+0.01%) As of 03/28/2025 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period Swiss National Bank Raises Stock Position in Apogee Therapeutics, Inc. (NASDAQ:APGE)Swiss National Bank raised its stake in shares of Apogee Therapeutics, Inc. (NASDAQ:APGE - Free Report) by 17.5% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 44,300 shares of theMarch 30 at 3:25 AM | marketbeat.comIs Apogee Therapeutics (APGE) Among the Best IPO Stocks to Buy in 2025?March 27, 2025 | msn.com12 Best IPO Stocks to Buy in 2025March 24, 2025 | insidermonkey.comApogee Therapeutics, Inc. (NASDAQ:APGE) Receives Average Rating of "Buy" from AnalystsShares of Apogee Therapeutics, Inc. (NASDAQ:APGE - Get Free Report) have earned an average rating of "Buy" from the six analysts that are covering the firm, MarketBeat reports. Six equities research analysts have rated the stock with a buy recommendation. The average 1-year target price among brokMarch 24, 2025 | marketbeat.comIntech Investment Management LLC Raises Stock Position in Apogee Therapeutics, Inc. (NASDAQ:APGE)Intech Investment Management LLC lifted its stake in Apogee Therapeutics, Inc. (NASDAQ:APGE - Free Report) by 232.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 16,934 shares of the company's stock after purcMarch 24, 2025 | marketbeat.comPlatinum Investment Management Ltd. Decreases Stock Position in Apogee Therapeutics, Inc. (NASDAQ:APGE)Platinum Investment Management Ltd. cut its stake in Apogee Therapeutics, Inc. (NASDAQ:APGE - Free Report) by 11.2% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 95,646 shares of the company's stock after seMarch 20, 2025 | marketbeat.comErste Asset Management GmbH Makes New $1.10 Million Investment in Apogee Therapeutics, Inc. (NASDAQ:APGE)Erste Asset Management GmbH purchased a new stake in Apogee Therapeutics, Inc. (NASDAQ:APGE - Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 24,000 shares of the company's stockMarch 16, 2025 | marketbeat.comApogee Therapeutics (NASDAQ:APGE) Now Covered by CitigroupCitigroup began coverage on Apogee Therapeutics in a research report on Thursday. They issued a "buy" rating and a $95.00 price target on the stock.March 14, 2025 | marketbeat.comVictory Capital Management Inc. Sells 123,296 Shares of Apogee Therapeutics, Inc. (NASDAQ:APGE)Victory Capital Management Inc. lowered its stake in shares of Apogee Therapeutics, Inc. (NASDAQ:APGE - Free Report) by 35.6% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 223,062 shares oMarch 14, 2025 | marketbeat.comCitigroup Initiates Coverage of Apogee Therapeutics (APGE) with Buy RecommendationMarch 13, 2025 | msn.comApogee Therapeutics initiated with a Buy at CitiMarch 13, 2025 | markets.businessinsider.comApogee Therapeutics (NASDAQ:APGE) Earns "Outperform" Rating from WedbushWedbush reaffirmed an "outperform" rating and set a $90.00 price objective on shares of Apogee Therapeutics in a research report on Tuesday.March 12, 2025 | marketbeat.comApogee Therapeutics (NASDAQ:APGE) Stock Price Up 4.5% - Still a Buy?Apogee Therapeutics (NASDAQ:APGE) Shares Up 4.5% - What's Next?March 11, 2025 | marketbeat.comCarl Dambkowski Sells 1,590 Shares of Apogee Therapeutics, Inc. (NASDAQ:APGE) StockApogee Therapeutics, Inc. (NASDAQ:APGE - Get Free Report) insider Carl Dambkowski sold 1,590 shares of the company's stock in a transaction that occurred on Wednesday, March 5th. The shares were sold at an average price of $30.48, for a total value of $48,463.20. Following the sale, the insider now owns 251,033 shares in the company, valued at $7,651,485.84. The trade was a 0.63 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.March 8, 2025 | marketbeat.comInsider Selling: Apogee Therapeutics, Inc. (NASDAQ:APGE) CEO Sells 10,000 Shares of StockApogee Therapeutics, Inc. (NASDAQ:APGE - Get Free Report) CEO Michael Thomas Henderson sold 10,000 shares of the stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of $30.15, for a total transaction of $301,500.00. Following the transaction, the chief executive officer now directly owns 1,292,987 shares in the company, valued at approximately $38,983,558.05. This represents a 0.77 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.March 8, 2025 | marketbeat.comWedbush Research Analysts Lower Earnings Estimates for APGEApogee Therapeutics, Inc. (NASDAQ:APGE - Free Report) - Investment analysts at Wedbush cut their Q1 2025 earnings per share (EPS) estimates for Apogee Therapeutics in a research note issued on Monday, March 3rd. Wedbush analyst D. Nierengarten now expects that the company will earn ($1.24) per shMarch 7, 2025 | marketbeat.comApogee Therapeutics (NASDAQ:APGE) Sets New 52-Week Low Following Weak EarningsApogee Therapeutics (NASDAQ:APGE) Sets New 52-Week Low on Disappointing EarningsMarch 5, 2025 | marketbeat.comApogee Therapeutics Reports 2024 Financial Results and Pipeline ProgressMarch 3, 2025 | tipranks.comApogee Therapeutics (NASDAQ:APGE) Stock Price Up 7.4% - Time to Buy?Apogee Therapeutics (NASDAQ:APGE) Stock Price Up 7.4% - Still a Buy?March 3, 2025 | marketbeat.comApogee Therapeutics (NASDAQ:APGE) Receives "Outperform" Rating from WedbushWedbush reaffirmed an "outperform" rating and issued a $90.00 price objective on shares of Apogee Therapeutics in a research note on Monday.March 3, 2025 | marketbeat.comApogee Therapeutics' Investigational Atopic Dermatitis Potential Shows Strong Tolerability, Extended Half-Life in Early TrialMarch 3, 2025 | benzinga.comApogee Therapeutics price target raised to $116 from $110 at GuggenheimMarch 3, 2025 | markets.businessinsider.comApogee Therapeutics (NASDAQ:APGE) Issues Quarterly Earnings ResultsApogee Therapeutics (NASDAQ:APGE - Get Free Report) posted its earnings results on Monday. The company reported ($1.19) earnings per share for the quarter, missing analysts' consensus estimates of ($0.94) by ($0.25).March 3, 2025 | marketbeat.comApogee Therapeutics Provides Pipeline Progress and Reports Full Year 2024 Financial ResultsMarch 3, 2025 | globenewswire.comApogee Therapeutics Announces Positive Interim Phase 1 Results from the APG990 Healthy Volunteer Trial, Unlocking Potential Maintenance Dosing Every Three and Six Months for APG279 (APG777 + APG990)March 3, 2025 | globenewswire.comIs Apogee Therapeutics, Inc. (APGE) the Best Small-Cap Stock to Buy Now?March 1, 2025 | insidermonkey.comApogee Therapeutics to Host Conference Call to Report Interim Results from the Phase 1 Healthy Volunteer Trial for APG990 and Provide Combination Strategy Update on March 3, 2025February 28, 2025 | globenewswire.comApogee Therapeutics, Inc. (NASDAQ:APGE) Given Average Rating of "Buy" by BrokeragesShares of Apogee Therapeutics, Inc. (NASDAQ:APGE - Get Free Report) have been given an average recommendation of "Buy" by the seven research firms that are covering the company, MarketBeat.com reports. Seven investment analysts have rated the stock with a buy rating. The average 12 month price tarFebruary 27, 2025 | marketbeat.comApogee Therapeutics (NASDAQ:APGE) Reaches New 12-Month Low - Here's WhyApogee Therapeutics (NASDAQ:APGE) Sets New 1-Year Low - Should You Sell?February 25, 2025 | marketbeat.comApogee Therapeutics to Participate in Upcoming March Investor ConferencesFebruary 25, 2025 | globenewswire.comApogee Therapeutics (APGE) to Release Earnings on TuesdayApogee Therapeutics (NASDAQ:APGE) will be releasing earnings before the market opens on Tuesday, March 4.February 25, 2025 | marketbeat.comApogee Therapeutics (NASDAQ:APGE) Reaches New 12-Month Low - Here's What HappenedApogee Therapeutics (NASDAQ:APGE) Reaches New 52-Week Low - Here's WhyFebruary 20, 2025 | marketbeat.comBank of America Securities Remains a Buy on Apogee Therapeutics (APGE)February 13, 2025 | markets.businessinsider.comApogee Therapeutics (NASDAQ:APGE) Stock Price Down 7.1% - What's Next?Apogee Therapeutics (NASDAQ:APGE) Trading Down 7.1% - Should You Sell?February 11, 2025 | marketbeat.comApogee Therapeutics' (APGE) Buy Rating Reaffirmed at GuggenheimGuggenheim reiterated a "buy" rating on shares of Apogee Therapeutics in a report on Monday.February 10, 2025 | marketbeat.comApogee Therapeutics' chief medical officer sells $143,228 in stockFebruary 8, 2025 | msn.comApogee Therapeutics, Inc. (NASDAQ:APGE) Insider Carl Dambkowski Sells 3,520 SharesApogee Therapeutics, Inc. (NASDAQ:APGE - Get Free Report) insider Carl Dambkowski sold 3,520 shares of Apogee Therapeutics stock in a transaction on Wednesday, February 5th. The shares were sold at an average price of $40.69, for a total transaction of $143,228.80. Following the completion of the transaction, the insider now directly owns 252,623 shares of the company's stock, valued at $10,279,229.87. The trade was a 1.37 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.February 7, 2025 | marketbeat.comApogee Therapeutics, Inc. (NASDAQ:APGE) CEO Michael Thomas Henderson Sells 15,000 SharesApogee Therapeutics, Inc. (NASDAQ:APGE - Get Free Report) CEO Michael Thomas Henderson sold 15,000 shares of the company's stock in a transaction that occurred on Wednesday, February 5th. The shares were sold at an average price of $40.58, for a total transaction of $608,700.00. Following the transaction, the chief executive officer now directly owns 1,302,987 shares in the company, valued at $52,875,212.46. The trade was a 1.14 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link.February 7, 2025 | marketbeat.comApogee announces first patient dosed in Part B of Phase 2 APEX trialFebruary 4, 2025 | markets.businessinsider.comApogee Therapeutics Announces First Patient Dosed in Part B of Phase 2 APEX Trial of APG777 in Patients with Moderate-to-Severe Atopic DermatitisFebruary 3, 2025 | globenewswire.comApogee Therapeutics, Inc. (NASDAQ:APGE) Given Consensus Recommendation of "Buy" by BrokeragesShares of Apogee Therapeutics, Inc. (NASDAQ:APGE - Get Free Report) have been assigned an average rating of "Buy" from the seven analysts that are currently covering the firm, MarketBeat.com reports. Seven investment analysts have rated the stock with a buy rating. The average 12-month price targeFebruary 2, 2025 | marketbeat.comApogee Therapeutics to Participate at the Guggenheim SMID Cap Biotech ConferenceJanuary 29, 2025 | globenewswire.comApogee Therapeutics: No Clinical Efficacy Data, Strong Competition, High Market CapJanuary 28, 2025 | seekingalpha.comApogee Therapeutics (NASDAQ:APGE) Shares Down 4.6% - Here's WhyApogee Therapeutics (NASDAQ:APGE) Trading Down 4.6% - Here's WhyJanuary 16, 2025 | marketbeat.comInsider Selling: Apogee Therapeutics, Inc. (NASDAQ:APGE) CEO Sells 15,000 Shares of StockJanuary 11, 2025 | insidertrades.comApogee Therapeutics (NASDAQ:APGE) Stock Price Down 9.1% - Should You Sell?Apogee Therapeutics (NASDAQ:APGE) Trading Down 9.1% - What's Next?January 10, 2025 | marketbeat.comApogee Therapeutics, Inc. (NASDAQ:APGE) Receives Average Recommendation of "Buy" from AnalystsShares of Apogee Therapeutics, Inc. (NASDAQ:APGE - Get Free Report) have been given an average rating of "Buy" by the seven research firms that are covering the company, Marketbeat.com reports. Seven analysts have rated the stock with a buy rating. The average 12 month price objective among brokerJanuary 8, 2025 | marketbeat.comApogee Therapeutics, Inc. (NASDAQ:APGE) Insider Carl Dambkowski Sells 4,085 SharesJanuary 4, 2025 | insidertrades.comCarl Dambkowski Sells 4,085 Shares of Apogee Therapeutics, Inc. (NASDAQ:APGE) StockApogee Therapeutics, Inc. (NASDAQ:APGE - Get Free Report) insider Carl Dambkowski sold 4,085 shares of the business's stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $46.94, for a total transaction of $191,749.90. Following the transaction, the insider now owns 255,348 shares of the company's stock, valued at $11,986,035.12. This represents a 1.57 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.January 3, 2025 | marketbeat.comThis Apogee Therapeutics Insider Increased Their Holding In The Last YearDecember 25, 2024 | finance.yahoo.com Remove Ads Get Apogee Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for APGE and its competitors with MarketBeat's FREE daily newsletter. Email Address APGE Media Mentions By Week APGE Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. APGE News Sentiment▼1.500.82▲Average Medical News Sentiment APGE News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. APGE Articles This Week▼63▲APGE Articles Average Week Remove Ads Get Apogee Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for APGE and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies RVMD News Today LNTH News Today TGTX News Today LEGN News Today BBIO News Today AXSM News Today TLX News Today BPMC News Today KRYS News Today NUVL News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:APGE) was last updated on 3/31/2025 by MarketBeat.com Staff From Our PartnersA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredJust Revealed: The chip company making AI look primitiveIn his just-released video presentation, this renowned market strategist — who's been called "one of the most ...InvestorPlace | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Apogee Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Apogee Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy APGE Stock Free APGE Stock Alerts